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Abstract: We have entered the Age of the Micro-
biome, with new studies appearing constantly and
whole journals devoted to the human microbiome.
While bacteria outnumber other gut microbes by
orders of magnitude, eukaryotes are consistently found
in the human gut and are represented primarily by the
fungi. Compiling 36 studies 1917–2015 we found at
least 267 distinct fungal taxa have been reported
from the human gut, and seemingly every new study
includes one or more fungi not previously described
from this niche. This diversity, while impressive, is illu-
sory. If we examine gut fungi, we will quickly observe a
division between a small number of commonly
detected species (Candida yeasts, Saccharomyces and
yeasts in the Dipodascaceae, and Malassezia species)
and a long tail of taxa that have been reported only
once. Furthermore, an investigation into the ecology
of these rare species reveals that many of them are
incapable of colonization or long-term persistence in
the gut. This paper examines what we know and have
yet to learn about the fungal component of the gut
microbiome, or “mycobiome”, and an overview of
methods. We address the potential of the field while
introducing some caveats and argue for the necessity
of including mycologists in mycobiome studies.
Key words: Candida, human health, microbiome, next-
generation sequencing
INTRODUCTION
All surfaces of the human body exposed to the envi‐
ronment are colonized with complex and diverse
populations of microorganisms from all three domains
of life (Clemente et al. 2012). A majority of the
microbes colonizing the human host reside within
the gastrointestinal (GI) tract, making the GI tract
home to one of the densest microbial communities
on Earth. Approximately 100 trillion microorganisms
inhabit the human gut and outnumber human host
cells by a factor of 10 to 1 (Whitman et al. 1998). This
population of microbes, collectively termed the gastro-
intestinal microbiota, has received much attention and
has been at the forefront of biological research for the
past decade.
Microbial numbers increase in a gradient from the
stomach to the colon (Schulze and Sonnenborn
2009). The upper gastrointestinal tract (stomach, duo-
denum, jejunum, proximal ileum) contains a relatively
low number of microorganisms. Few organisms (,102
cells/mL), consisting of acid-tolerant lactobacilli and
streptococci, are present in the stomach and upper
small intestine due to harsh pH conditions (Mackie
et al. 1999). Cell densities in the proximal small intes-
tine are 104–105 cells/mL of intestinal content (Walter
and Ley 2011). The lower gastrointestinal tract (distal
ileum, colon) contains a much higher population
and diversity of microorganisms—108 cells/gram in
the distal ileum and approaching 1010–1012 cells/
gram in the colon. Higher pH, low concentration of
bile acids and longer retention due to slower peristalsis
are several properties that distinguish the colon from
the rest of the GI tract and allow it to be the primary
site of colonization (Walter and Ley 2011). This allows
easily-collected fecal samples to provide a reasonable
snapshot of the gut microbiome.
Bacteria are the most abundant microorganisms in
the gastrointestinal tract: more than 99% of the genes
in the human gut microbiome are of bacterial origin
and the number of bacterial species reported from
the gut is generally estimated at 500–1000 (Xu and
Gordon 2003, Qin et al. 2010). Current evidence sug-
gests members of the kingdom Archaea reside along-
side bacteria in the gut, albeit in much lower
numbers (Qin et al. 2010). Two large-scale projects,
the Human Microbiome Project and MetaHit, provide
an initial compilation of the gut microbiome ecosys-
tem from 242 and 124 humans, respectively (NIH
HMP Working Group et al. 2009, Qin et al. 2010,
Human Microbiome Project Consortium 2012). One
study involving fecal samples from 124 Europeans
showed each individual harbored at least 160 species
of bacteria and a majority of the species was shared
among individuals (Qin et al. 2010). As revealing as
the results have been, studies to date from these proj‐
ects focused exclusively on the bacterial component
and other kingdoms were not considered. Smaller-
scaled, fungal-specific studies using culture-dependent
and/or culture-independent methods thus have been
conducted but are limited.
Eukaryotes in the human gut are less extensively stud‐
ied than prokaryotes, yet remain an important com‐
ponent of the microbiome. The protist Blastocystis
and fungi (as a group) both have been reported as
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the dominant eukaryotes in the gut (Rajilic-Stojanovic
et al. 2007, Nam et al. 2008, Scanlan and Marchesi
2008). The term mycobiome was coined in 2010 to dif-
ferentiate the fungal biota from the bacterial biota, in
that the word “microbiota” is frequently treated as
synonymous with bacteria (Ghannoum et al. 2010).
On 6 Jul 2013, using a PubMed search, the word
“mycobiome” appeared in the literature 10 times
(Cui et al. 2013), while a 7 Jun 2015 search yielded at
least 38 “mycobiome” studies. “Mycome”, coined in
2014 (Ianiro et al. 2014), also has been suggested.
Every human being is colonized with fungi, and fun-
gal populations colonize the human host at multiple
body sites—gastrointestinal tract, oral cavity, skin, vagi-
nal tract and lungs (Ghannoum et al. 2010, Drell et al.
2013, Findley et al. 2013, Hoffmann et al. 2013, Huff-
nagle and Noverr 2013, van Woerden et al. 2013). Dif-
ferent fungi are associated with different body sites,
with the skin harboring near-monotypic assemblages
dominated by Malassezia species, while the most
diverse assemblages are found in the oral cavity and
gastrointestinal tract (Underhill and Iliev 2014).
Many human-associated fungi are opportunistic patho-
gens in that disease is caused when the host defense
system becomes weakened. Well-known fungal infec-
tions range from skin mycoses such as athlete’s foot,
ringworm and yeast infections to life-threatening sys-
temic mycoses caused by Cryptococcus, Candida, Aspergil-
lus, Coccidioides and Pneumocystis. An estimated 75% of
women will suffer a yeast infection during their life-
time and roughly 20–25% of the world’s population
has skin mycoses (Sobel 2007, Havlickova et al. 2008).
Fungi represent the majority of eukaryotes in the
human gut microbiome and the remainder of this
review will detail and depict what is currently known
about the relatively new field of human gut mycology.
GASTROINTESTINAL COLONIZATION BY FUNGI
Gastrointestinal microbial colonization starts at birth.
The vaginal tract is home to a large number of yeasts
and, not surprisingly, neonates born vaginally are colo-
nized by yeasts from their mother’s vaginal microbiota
(Bliss et al. 2008). Infant colonization by Candida spp.
is therefore transmitted vertically from the maternal
microbiota and also horizontally from the environ-
ment and hands of family members and health care
workers (Lupetti et al. 2002, Bliss et al. 2008). The prev‐
alence of Candida spp. gut colonization in newborns
on the day of birth is roughly 23%, increasing to 50%
by 4 mo (Ellis-Pegler et al. 1975, Saiman et al. 2001).
Yeast carriage rates in infants are approximately
103–105 CFU/g feces (Ellis-Pegler et al. 1975, Benno
et al. 1984).
Fungi are detectable in all sections of the GI tract of
about 70% of healthy adults, normally at up to 103 fun-
gal cells per mL or g of intestinal contents (Schulze
and Sonnenborn 2009). Culture-independent analyses
show fungal genes constitute less than 0.1% of the
human gut microbiome (Qin et al. 2010). The low
abundance of fungi in the gut microbiome undoubt-
edly relegates them to part of the “rare biosphere”
(Sogin et al. 2006). The rare biosphere is of signifi-
cance in that it potentially serves as a reservoir for
pathogens or keystone species that have a critical role
in maintaining the structure and function of the
human gut microbiome (Huffnagle and Noverr 2013).
The oral cavity, which provides a direct route of
entry to the gastrointestinal tract, is asymptomatically
colonized by Candida and harbors a wide diversity of
fungi, likely from food and airborne spores (Arendorf
and Walker 1979, Ghannoum et al. 2010). The rapid
luminal flow and low pH of gastric acid lets few micro-
organisms colonize the stomach and functions as a bar-
rier to prevent ingested pathogens from reaching the
intestine (Martinsen et al. 2005). A number of acid-
resistant bacteria exist in the stomach as well, such as
a few acid-tolerant fungi like Candida and Phialemonium
(Bik et al. 2006, von Rosenvinge et al. 2013). The diver-
sity of fungi in the small intestine is largely unexplored
due to the difficulty in collecting samples (Wang et al.
2014). Ileal effluent collected from intestinal trans-
plant recipients showed colonization by Saccharomyces
cerevisiae, Candida spp., Cryptococcus neoformans and
Aspergillus clavatus (Li et al. 2012). The properties of
the large intestine facilitate extensive microbial coloni-
zation and proliferation, and a wide diversity of fungal
genes is detected in the lower gastrointestinal tract.
METHODS FOR CHARACTERIZING THE GASTROINTESTINAL
FUNGAL COMMUNITY
The first studies taxonomically identifying the fungi of
the gastrointestinal tract (as opposed to merely docu-
menting the presence of fungi without identification)
date to the early 1900s (Kohlbrugge 1901, Anderson
1917). The ability to culture fungi was critical for iden-
tification. At the time it was known that feces contain a
large number of bacteria compared to fungi and
ordinary culture medium and plating methods would
not be sufficient for the isolation of fungi from the
gut. Therefore media inhibiting bacterial growth,
such as Sabouraud’s agar, were commonly used (Ash-
ford 1915, Anderson 1917). Historically identification
and classification of yeasts was based on readily observ‐
able gross colony features (color, size, shape), micro-
scopic examination and biochemical properties.
Although advances have been made in culture-
dependent methods, these methods present several
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disadvantages that restrict the ability of mycologists to
accurately characterize fungi in fecal samples. In cul-
ture-based studies, dominant populations (e.g. Can-
dida spp.) can mask the detection and diversity of
low-abundance organisms. In addition, current fungal
culture techniques may be inadequate to optimally cul-
tivate organisms that require microbe-microbe interac-
tions because culture fails to reproduce ecological
niches and symbiotic relationships encountered in
the natural environment (Carraro et al. 2011, Beck
et al. 2012). The culturable fraction also is distorted
because replication times vary among microorganisms
and fast-growing species efficiently outcompete others
(Nocker et al. 2007).
The development of PCR in the 1980s revolution‐
ized fungal detection methods (Saiki et al. 1985),
and high-throughput nucleic acid sequencing has
become the preferred method for mycobiome studies
(Dollive et al. 2012, David et al. 2014). Sequencing
techniques are capable of distinguishing species
with genes within the fungal ribosomal RNA gene
cluster—18S small subunit rDNA, 28S large subunit
rDNA and the internal transcribed spacer (ITS1 or
ITS2). rRNA genes are appealing targets for fungal
identification because they are highly multicopy in
each genome. Fungal rRNA genes have highly con-
served regions serving as primer binding sites to deter-
mine the sequences of adjacent variable regions by
PCR amplification. In fungi 28S provides much greater
resolution than 18S and continues to be used for
within-genus (i.e. species-level) identification and phy-
logenetic studies, while 18S is rarely adequate to distin-
guish species (Das et al. 2014) (in contrast with the
analogous bacterial 16S gene, which is widely used
for identification). ITS genes are less conserved and
therefore are considered the best target for fungal spe-
cies and subspecies identification (Porter and Golding
2012, Schoch et al. 2012). PCR and sequencing biases
exist, notably a bias toward shorter sequences with Illu-
mina MiSeq and especially Ion Torrent methodologies
(Tang et al. 2015). Nonetheless next-generation se‐
quencing of these genes has provided the most accu-
rate account of the fungal composition of the human
gut microbiome.
Since 2008 the most commonly used methods for
identifying gut fungi involve some form of ITS sequenc‐
ing coupled with a BLAST query, both of which have
limitations. ITS sequence is insufficient to differentiate
between certain closely related species (e.g. Alternaria
alternata, A. brassicicola and A. tenuissima or Cladospo‐
rium cladosporioides, C. bruhnei, C. herbarum/Davidiella
tassiana, C. macrocarpum, C. sphaerospermum and C.
tenuissimum), so the exact number and identities of
species reported remains undetermined. BLAST
results also are subject to the limits of the relevant
database, a limitation made clear in a study in which
the dominant fungus recovered from the gut had
“sequences 100% identical to both Gloeotinia tem‐
ulenta (DQ235697) and P[aecilomyces] fumosoroseus
(AB086629)” (Scanlan and Marchesi 2008). These
GenBank accessions indeed are identical, but the spe-
cies’ ITS sequences are not; one is misidentified. In
addition to misidentifications databases may contain
multiple names for one organism (especially ana-
morphs and teleomorphs) or may contain insufficient
information to lead to an identification (“soil fungus”,
“unclassified ascomycete” etc.) (Tang et al. 2015).
Efforts are underway to develop and maintain curated
sequence databases, and Tang and colleagues (2015)
report the development of a targeted host-associated
fungi (THF) ITS database specifically for microbiome
samples.
Metagenomic sequencing has become common for
bacterial microbiome studies and offers the advantage
of functional characterization—identifying not only
members of the microbiome but also the functions
they perform, for example, inulin breakdown or buty-
rate production (Walter and Ley 2011). To date this
approach has not been adopted for fungi, due to the
lack of a good, culture-independent, method of sepa‐
rating out fungi from the thousandfold more abun-
dant bacteria. However, genome sequence is available
for many of the fungi most likely to be true members
of a gut community (e.g. Candida albicans and other
opportunistic Candida species). With the use of such
annotated genomes and transcriptomic data, the
potential for metagenomic studies to yield valuable
information about the activities of particular fungi
is high.
A few studies have used a combination of culture-
dependent and -independent methods for the identifi-
cation of gut fungi and compared the results. One
study exploring the diversity of gut eukaryotes in a
Senegalese man identified 16 fungal species by molec‐
ular methods targeting the ITS, 18S and 28S genes and
only four fungal species by culturing, using three cul-
ture media (Hamad et al. 2012). Three of the four
fungi isolated by culture also were detected by sequenc‐
ing; the exception was C. krusei. An earlier study also
highlighted a culturing bias. Candida spp. were identi-
fied as predominant by cultivation methods while
“Gloeotinia/Paecilomyces” and Galactomyces were found
to be the predominant species using clone libraries
(Scanlan and Marchesi 2008). Chen and colleagues
found 37 fungal OTUs using clone libraries while
only five species, from two genera (Candida and Sac-
charomyces), were isolated on two culture media
(Chen et al. 2011). Of interest, two of these five species
were not detected by cloning and sequencing, which
failed to detect C. krusei and C. glabrata.
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COMPOSITION OF THE GASTROINTESTINAL
FUNGAL COMMUNITY
Previous culture-dependent studies identified Candida
spp. as the most common (if not the only) fungi in
the GI tract. With the development of advanced cultur-
ing methodologies and PCR, the modern era of myco-
biome studies has exposed a more in-depth survey of
both culturable and unculturable fungi in the gut. At
present only a handful of mycobiome characterization
studies exist. We compiled a list of fungal species
reported from the GI tract of humans (TABLE I, SUP-
PLEMENTARY TABLE I; include: healthy and diseased
adults and infants; fungi from stomach, small intestine,
large intestine; differing diets and varying geographic
locations), from articles spanning 1917–2015. If a
more current name for a fungus exists than that used
in the initial study, the current name is also listed.
Fungi reported from the literature but not specified
to the species are excluded from the list if a species
from that genus, family or class is listed (e.g. Candida
sp., Capnodiales sp.). Fungi that cannot be identified
(“unclassified ascomycete”, “unclassified fungus”) are
omitted. Taxa reported in the literature that are indis-
tinguishable from one another at the level of the target
gene used are listed in the same row. One list (TABLE I)
is limited to those fungi reported in more than one
study and is organized by broad ecological categories;
a comprehensive, alphabetical list, including those
fungi reported only once is provided (SUPPLEMENTARY
TABLE I.
The most commonly detected fungi in the GI tract
of humans among the 35 studies listed (TABLE I) are
C. albicans (25 studies), Saccharomyces cerevisiae (19), C.
tropicalis (17), C. parapsilosis (13), C. glabrata (12), C.
krusei (10), Cladosporium cladosporioides (10), Penicillium
allii (10), Malassezia globosa (8), M. restricta (7), Debaryo-
myces hansenii (7) and Galactomyces geotrichum (7). Can-
dida species are known to dominate the GI tract of
humans, and their presence is not surprising. At least
267 distinct fungal taxa have been reported in the
gut, which is considerably lower than the estimated
500–1000 bacterial taxa residing therein (Xu and Gor-
don 2003, Qin et al. 2010). In addition, a majority of
the fungi (200; SUPPLEMENTARY TABLE I) were reported
only in one study. While approximately 40% of the fun-
gal taxa reported from the gut are yeasts, yeasts repre-
sent 63.4% of the taxa reported from multiple studies,
and 10 of the 12 most commonly detected fungi are
yeasts.
We provide a conservative classification of fungi by
niche (TABLE I), in which the classifications come
from the literature or frequently the substrate of the
type specimen. This classification is broadly correct
but subjected to some caveats; for example, the type
of Candida intermedia was isolated from feces, but every
taxon (TABLE I) has been detected in feces, so fecal iso-
lation does not necessarily indicate the primary habi-
tat. Taxa for which the niche is listed as “other” have
commonly been isolated from a wide variety of
substrates.
Unlike bacteria, for which evidence exists for a “core
microbiome” of varying but related species performing
a defined set of metabolic functions and ecologic roles,
shared by much of the human population (Lozupone
et al. 2012), evidence for a stable “core mycobiome”
is lacking. A small number of species, largely Saccharo-
mycetalean yeasts, are reported from multiple samples
in multiple studies, while more than two-thirds of all
reported species are detected only in a single sample
and/or study (Hallen-Adams et al. 2015, Suhr 2015;
SUPPLEMENTARY TABLE I). The majority (77%) of taxa
detected in a single study were detected by nonculture
methods, and thus may have been nonviable. An
understanding of fungal ecology and physiology sug-
gests that even relatively commonly detected gut fungi
(e.g. Debaryomyces hansenii and multiple Penicillium spe-
cies, which do not grow at 37 C, and plant-pathogenic
Alternaria species) are allochthonous, passing through
from environmental or dietary exposure without colo-
nizing the gut or exerting any influence on the gut
microbiota or host.
We propose that the 10 Candida species whose niche
is categorized as “Human/mammalian GI tract”
(TABLE I)—Candida albicans, C. tropicalis, C. parapsilosis,
C. glabrata, C. krusei, C. lusitaniae, C. dubliniensis, C.
rugosa, C. orthopsilosis and C. intermedia—are predomi-
nantly gut organisms. Furthermore, based on fre-
quency of detection combined with imperfect/
uncertain ITS sequence identification, Malassezia
species (reported from six, seven and eight studies),
Cladosporium species (10 studies) and Galactomyces geo-
trichum (seven studies) deserve closer scrutiny as possi-
ble gut organisms, as does Saccharomyces cerevisiae (19
studies). The ubiquity of S. cerevisiae in food and drink
may go far toward explaining its abundance; its ability
to persist in the gut deserves further study. The only
filamentous fungus in this list is Cladosporium, whose
presence may prove to be attributable solely to environ‐
mental abundance. We consider the other fungi
reported from the gut as incidental and unlikely to
form a lasting part of any gastrointestinal microbial
community, on the basis of physiological constraints
(many Penicillium species do not grow at 37 C; Wallemia
species are extreme xerophiles and would not grow at
the water-activity found in the human body) or known
ecological niche (Ustilago maydis is an obligate patho-
gen of maize).
We illustrate (TABLE I, SUPPLEMENTARY TABLE I) the
dynamic and variable nature of the mycobiome in
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the number of studies identifying a given fungus and
conversely the number of fungi identified in a single
study. To address the stability of the mycobiome, a
study would need to enroll sufficient subjects and
obtain a sufficient number of samples from each sub-
ject over time to allow statistically significant conclu-
sions to be drawn; to date this has not been done in
humans. In the mouse gut fungal populations vary sub-
stantially over time and are influenced by the environ-
ment, while bacterial populations remain relatively
stable (Dollive et al. 2013). There are both more bac-
terial species and more individual bacteria in the gut
than fungi and thus bacterial communities may be
more robust (Underhill and Iliev 2014).
It is common for mycobiome papers to report all
fungal taxa identified in their studies, frequently draw-
ing attention to first reports of species from the gut.
Unfortunately to date few mycologists have turned
their attention to the human mycobiome, leading to
several common errors in mycobiome studies that
would be—not absent but less pronounced—if the
research were being conducted by those familiar with
the organisms. Misspellings (including of the model
organism “Saccharomyces cerevisiae”, for which we have
seen six non-canonical spellings) are common; how-
ever, our own experience suggests that these are as
likely to occur in review or proof as at the authors’
hands. Even with the adoption of “one fungus, one
name” in the Melbourne Code (McNeill et al. 2012),
fungal nomenclature remains an esoteric study and
species are reported as “new” to the gut when in fact
they were reported in earlier studies under one or
more names.
THE GUT MYCOBIOME IN HEALTHY AND DISEASED STATES
Since Hippocrates first described oral candidiasis in
400 BC, researchers and clinicians have aimed to
explore the roles of commensal and pathogenic fungi
in human health and disease (Adams 1939). Com-
pared to the vast amount of literature on the benefits
of bacteria in the human gut, the beneficial role of
gut fungi, if any, remains largely unexplored. No
strong evidence exists for a mutualistic or beneficial
relationship between the host and the gut mycobiome
(Huffnagle and Noverr 2013). The only living fungus
studied in detail with any indications of conferring a
health benefit is the probiotic yeast Saccharomyces cerevi-
siae var. boulardii (“S. boulardii”) (Zanello et al. 2009).
Clinical trials using S. boulardii as a therapeutic strategy
have shown significant efficacy in treatment and pre-
vention for various types of diarrhea including trav‐
eler’s diarrhea, antibiotic associated diarrhea and
inflammatory bowel disease (Guslandi et al. 2000,
2003; McFarland 2007; Bravo et al. 2008). In addition
to the presumed health benefits, it is proposed that
probiotic yeasts may positively interact with probiotic
bacteria by enhancing their survival and overall display
a synergistic effect (Bik et al. 2006, Suharja et al. 2014).
Another potential medical application of probiotic
yeasts involves their ability to express disease-fighting
proteins known as killer toxins, or mycocins, against
pathogenic yeasts, such as Candida spp. (Weiler
et al. 2003).
Yeasts first were detected in the human GI tract in
the early 19th century (Langenbeck 1842). In the early
1900s the presence of yeasts in feces was sporadically
documented in the medical literature and studies tried
to link their presence to gastrointestinal diseases, such
as sprue (a digestive disease characterized by malab-
sorption commonly reported in tropical regions) (Le
Dantec 1908, Ashford 1915, Brabander et al. 1957).
Years later, just before World War II, isolates from
human clinical samples were identified as yeasts of
the genus Monilia, which later were reclassified into
the genus Candida (Martin et al. 1937, Langeron and
Guerra 1938, Martin and Jones 1940). Candida from
the intestines of healthy individuals and those with gas-
trointestinal disturbances became a popular area of
research during the mid-20th century. Candida was
the most commonly isolated yeast from fecal samples,
yet its significance and occurrence in stools had yet
to be elucidated due to the fact that heavy loads of Can-
dida species were collected from healthy humans (Bra-
bander et al. 1957). The history of Candida detection
in disease states and known ability of Candida yeasts
to cause infection led physicians in the late 1980s to
propose hypotheses linking unhealthy habits to Can-
dida overgrowth in the intestine (Truss 1981, Schulze
and Sonnenborn 2009). Mycophobia was spreading
due to the false interpretation of yeasts isolated from
the mouth or stool as fungal infections (Seebacher
1996). The persistence of mycophobic attitudes may
be readily observed by anyone performing a web
search on “Candida”.
Characterizing fungal populations (species composi-
tion, diversity, relative abundance, alterations in the
fungal community) during different disease states
may inform knowledge of cause and effect. In the gut
higher fungal diversity has been observed in patients
with Crohn’s disease, hepatitis B and pouchitis than
in healthy individuals (Kübacher et al. 2006, Ott et al.
2008, Chen et al. 2011, Li et al. 2014). However, this
is not the case for the mycobiome at other diseased
body sites. Drawing broad conclusions about fungal
diversity, colonization and disease is difficult due to
the low number of studies, sample numbers and uncer-
tainty across body sites.
The most common yeasts associated with disease are
Candida, Histoplasma, Blastomyces and Cryptococcus and
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TABLE I. Fungi reported in multiple studies from the gastrointestinal tract of humans
Niche Fungal taxa
Human/mammalian GI tract Candida albicans2 (1, 3, 4, 6, 7, 9, 11, 12, 15, 16, 19, 20, 21, 22, 23, 24, 26, 28, 29, 30, 31, 32, 35)
(also reported as Endomyces albicans1 [2], Oidium albicans1 (2), Parasaccharomyces
ashfordii1 [2])
Candida tropicalis2 (1, 3, 4, 5, 6, 7, 13, 16, 20, 21, 22, 23, 31, 32, 34, 35) (also reported as Monilia
candida Bon.1 [2])
Candida parapsilosis2 (3, 4, 5, 7, 16, 20, 21, 22, 24, 28, 32, 33, 35)
Candida glabrata2 (1, 4, 6, 15, 19, 20, 21, 24, 26, 30) (also reported as Cryptococcus glabratus1 [2],
Torulopsis glabrata1 [7])
Candida krusei1 (1, 3, 4, 6, 7, 17, 20, 24, 32) (also reported as Mycoderma monosa1 [2]), current
name: Candida acidothermophilum
Candida lusitaniae2 (1, 3, 4, 5, 20) (also reported as Clavispora lusitaniae2 [15])
Candida dubliniensis (15, 22, 23, 26)
Candida rugosa2 (16, 17, 20) (also reported as Mycoderma rugosa1 [2])
Candida orthopsilosis2 (3, 5)
Candida intermedia2 (3, 6)
Human/mammalian
associated, elsewhere
Malassezia globosa2 (5, 8, 13, 14, 15, 17, 22, 31)
Malassezia restricta2 (5, 13, 14, 15, 16, 17, 31)
Malassezia pachydermatis2 (6, 13, 14, 15, 17, 31)
Candida guilliermondii1 (1, 3, 7, 20), current name: Blastodendrion artzii
Trichosporon asahii2 (3, 15, 17)
Blastoschizomyces capitatus1 (20) (also reported as Dipodascus capitatus [34]), current name:
Geotrichum capitatum
Candida zeylanoides1 (1) (also reported as Candida krissii [6])
Cryptococcus neoformans (22, 23)
Malassezia sympodialis (16, 31)
Trichosporon dermatis (5, 26)
Probable foodborne Saccharomyces cerevisiae2 (1, 3, 5, 6, 8, 14, 15, 16, 17, 19, 21, 22, 23, 24, 25, 26, 28, 31, 34)
Penicillium allii1 (13), P. camemberti2 (13), P. chrysogenum2 (15, 23, 26) (5 Penicillium notatum1
[7, 34]), P. commune (31, 34), P. dipodomyicola1 (13), P. freii (6), P. italicum (26), P. solitum (14)
Debaryomyces hansenii2 (5, 8, 15, 16, 31) (also reported as Candida famata1 (1, 19), D. fabryi [5])
Candida sake (16, 34) (also reported as Candida austromarina [6, 26])
Penicillium roqueforti (16, 28, 31, 34)
Aspergillus niger2 (7, 16, 31, 33)
Candida kefyr1 (1, 4, 19), current name: Atelosaccharomyces pseudotropicalis
Aspergillus flavus1 (14), Aspergillus oryzae (31)
Saccharomyces bayanus (5, 26)
Agaricus bisporus (10, 31)
Plant associated Cladosporium cladosporioides2 (5, 7, 21, 26, 31), C. bruhnei (14), C. herbarum1 (32) (5 Davidiella
tassiana2 [15, 16]), C. macrocarpum1 (33), C. sphaerospermum2 (21, 32, 33), C. tenuissimum (21)
Alternaria alternata (15, 31), A. brassicicola (23), A. tenuissima (31)
Sclerotinia sclerotiorum (15, 22, 23, 26)
Botryotinia fuckeliana (22, 26), current name: Botrytis cinerea
Fusarium graminearum (31), F. culmorum (16)
Fusarium oxysporum (22, 26)
Fomitopsis pinicola (15, 26)
Moniliophthora perniciosa (8, 23), current name: Crinipellis perniciosa
Ustilago maydis (8, 26)
Other Galactomyces geotrichum2 (6, 13, 15, 16, 17, 26, 28)
Aspergillus sydowii1 (34), Aspergillus versicolor2 (6, 7, 13, 28, 33)
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to a lesser extent species of Geotrichum, Malassezia,
Pichia, Rhodotorula, Saccharomyces and Trichosporon.
With the exception of Blastomyces, each of these fungal
genera has been reported in the GI tract; however,
with the exception of Candida, and Saccharomyces in
immunocompromised patients, yeasts in the gut are
not implicated in disease. The most common filamen-
tous fungi associated with disease and found in the gut
are Aspergillus species. While best known for causing
lung infections, gut aspergillosis is reported in patients
with blood malignancies (Kazan et al. 2011, Li et al.
2014). Other filamentous fungi found in the gut and
causing infections include Alternaria, Scedosporium, Pae-
cilomyces and Trichoderma; infections with these species
are much less common than with Aspergillus. In addi-
tion to involvement of specific fungi (notably Candida
species) in disease, an overall increase of gut fungal
diversity and/or abundance has been associated with
inflammatory bowel diseases, hepatitis B, pouchitis
and gastric ulcers (TABLE II and references cited
therein).
Candida species are normal, harmless commensals
on many human body sites and have been consistently
reported in gut fungi studies. Candida species resident
TABLE I. Continued
Niche Fungal taxa
Yarrowia lipolytica2 (8, 15, 20, 26)
Aureobasidium pullulans2 (6, 26, 32)
Chaetomium globosum (6, 8, 26)
Geotrichum candidum2 (17, 20) (also reported as Galactomyces candidum [15])
Aspergillus clavatus (22, 23)
Aspergillus fumigatus (31, 34)
Candida colliculosa1 (3, 4)
Candida sphaerica1 (1, 3)
Candida utilis1 (1, 3), current name: Candida guilliermondi var. niratophila
Cyberlindnera jadinii (31) (also reported as Pichia jadinii [16])
Eurotium rubrum (31) (also reported as Aspergillus ruber1 [14])
Glomerella sp. (16, 18)
Kluyveromyces hubeiensis (17, 27)
Metschnikowia sp. (16, 18)
Neosartorya fischeri (8, 31)
Saccharomyces castellii (22, 23), current name: Naumovia castellii
Sclerotium sp. (14, 26)
Rhodotorula mucilaginosa (15, 26) (also reported as Rhodotorula pilimanae1 [7])
Cryptococcus tephrensis (16, 31)
Cystofilobasidium capitatum2 (14, 26)
Filobasidium globisporum (15, 26)
Mrakia sp. (16, 31)
Rhodotorula glutinis1 (20) (also reported as Saccharomyces glutinous1 [2])
Torula rubra1 (2, 7), current name: Rhodotorula rubra
Wallemia muriae (6, 31)
Wallemia sebi (6, 10)
Note: No superscript indicates fungi were detected by culture-independent method.
1 Fungi were detected by culture-dependent method.
2 Fungi were detected by both culture-dependent and -independent methods.
References: (1) Agirbasli et al. 2005, (2) Anderson 1917, (3) Angebault et al. 2013, (4) Biasoli et al. 2002, (5) Cano et al. 2014,
(6) Chen et al. 2011, (7) Cohen et al. 1969, (8) David et al. 2014, (9) DiGiulio et al. 2008, (10) Dollive et al. 2012, (11) Finegold
et al. 1974, (12) Finegold et al. 1977, (13) Gouba et al. 2013, (14) Gouba et al. 2014a, (15) Gouba et al. 2014b, (16) Hallen-Adams
et al. 2015, (17) Hamad et al. 2012, (18) Hoffmann et al. 2013, (19) Jobst and Kraft 2006, (20) Khatib et al. 2001, (21) LaTuga
et al. 2011, (22) Li et al. 2012, (23) Li et al. 2014, (24) Macura and Witalis 2010, (25) Nam et al. 2008, (26) Ott et al. 2008, (27)
Pandey et al. 2012, (28) Scanlan and Marchesi 2008, (29) Soyucen et al. 2014, (30) Stewart et al. 2013, (31) Suhr 2015, (32) Tay-
lor et al. 1973, (33) Taylor et al. 1985, (34) Ukhanova et al. 2014, (35) von Rosenvinge et al. 2013.
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in the GI tract are considered a major reservoir and
source of infections such as invasive candidiasis (Nucci
and Anaissie 2001). C. albicans, the predominant gut
fungus, colonizes the GI tract but has the ability to
invade tissues and disseminate in the body when the
gut microbiome is disrupted, intestinal mucosal per-
meability is increased or the host is immune-sup-
pressed. Candida gut overgrowth has been associated
with a number of diseases such as diabetes, hematolog‐
ic malignancies, Crohn’s disease and graft vs. host dis-
ease and populations such as hospital inpatients and
extremely low birth weight infants (TABLE II). Patients
with gastrointestinal disorders such as ulcerative colitis
and Crohn’s disease are more frequently and heavily
colonized by C. albicans than are control groups (Ksiad-
zyna et al. 2009, Standaert-Vitse et al. 2009).
Malassezia is commonly reported in fecal samples
(Chen et al. 2011, Hamad et al. 2012, Li et al. 2012,
Gouba et al. 2013, Suhr 2015). Malassezia species are
the dominant fungi on the skin surfaces of mammals,
where they are dependent on the host for lipids and
are associated with various superficial skin diseases
and dandruff (Gupta et al. 2004) and may become
associated with feces through skin contact during defe-
cation. Conversely the availability of lipids in the GI
tract, particularly the small intestine, could select for
gut colonizing Malassezia species.
Aspergillus species have a worldwide distribution and
their ubiquity in the environment exposes humans to
Aspergillus spores daily. Invasive aspergillosis has
increased significantly in recent decades and is the
most common filamentous fungal lung infection in
immunocompromised patients (Groll et al. 1996,
McNeil et al. 2001), while noninvasive colonization of
the nasal cavities and lungs is common in immuno-
competent persons (Giri et al. 2013). Aspergillus fumiga-
tus is the most prevalent species of the 200 aspergilli
described and is the main cause of human infections
(Dagenais and Keller 2009); A. flavus, A. glaucus, A.
niger, A. nidulans, A. parasiticus and A. terreus also are
commonly associated with aspergillosis (Moore et al.
2011). Numerous species of Aspergillus have been
reported in the GI tract of humans (TABLE I), some
likely due to transit from the airways (Beck et al.
2012). Aspergillus species clearly possess the ability to
survive in and colonize the human body; however, spe-
cies detected in the gut also are common in the envir-
onment and/or colonizing food, and their presence in
the gut is likely a reflection of general abundance
rather than of persistent colonization.
MYCOBIOME AND HOST IMMUNITY
The GI tract is home to the majority of both the
human body’s commensal microorganisms andTA
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immune cells. Little is known about the interaction
between commensal intestinal fungi and the host
immune system. Several players of the immune system
have been reported to have critical roles in fungal
recognition and host defense against disseminated
fungal infections. These include Dectin-1, IL-17 and
IL-22 (Iliev and Underhill 2013). Dectin-1 is a C-type
lectin that plays a role in the innate immune response
by functioning as a pattern-recognition receptor and
recognizing beta-glucans found in the cell walls of
fungi. In mice Dectin-1 is of critical importance to
defend against pathogenic fungi such as Pneumocystis
carinii and C. albicans (Saijo et al. 2007, Taylor et al.
2007). Humans deficient in Dectin-1 suffer recurrent
mucocutaneous candidiasis infections (Ferwerda et al.
2009). Genetic polymorphisms of Dectin-1 also have
been associated with increased severity of ulcerative
colitis (Iliev et al. 2012, Underhill and Iliev 2014).
Cytokines IL-17 and IL-22 have been implicated in
mucosal and antifungal immunity. Mice deficient in
components of the IL-17 pathway have increased sus-
ceptibility to oral candidiasis and skin infections (Conti
et al. 2009, Kagami et al. 2010). Furthermore, IL-22
serves as a first line of defense against candidiasis in
mice because IL-22-deficient mice are more suscepti-
ble to GI candidiasis (de Luca et al. 2010). Mucosal
immune responses to fungi are different across human
body sites. A complete understanding of the interac-
tion between commensal fungi and the immune sys-
tem has yet to be unveiled.
DIET AND THE GASTROINTESTINAL MYCOBIOME
Diet is a known environmental factor that influences
the structure and diversity of microorganisms in the
gut. Resident bacterial populations are shown to be
associated with diet and long-term dietary patterns
(David et al. 2014). However, few studies have investi-
gated the relationship between diet and the human
intestinal mycobiome. One recent human study
demonstrated that consumption of high amounts of
carbohydrates was positively associated with Candida
spp. colonization, while a diet high in amino acids,
fatty acids and protein was negatively associated with
Candida spp. (Hoffmann et al. 2013). Fungal abun-
dance in the gastrointestinal tract also was associated
strongly with the composition of short-term diet. Diets
with meat significantly increase Penicillium spp. (David
et al. 2014), while Ukhanova et al. (2014) showed a
decrease in Candida and Penicillium species following
pistachio and almond consumption. Unsurprisingly
fungi consumed as part of the diet (edible mushrooms,
yeasts and Penicillium spp. involved in cheese making)
can be detected in fecal samples (David et al. 2014,
Suhr 2015).
Intestinal populations of microorganisms are sus-
pected of contributing to obesity by way of diet (Ley
et al. 2006). The role of gut fungi in obesity is
unknown. Only one study has addressed this, focusing
on the fungal communities in the human gut of a sin-
gle obese person and detecting 18 fungal species
(Gouba et al. 2013.). Conversely a study identifying
the fungal community of a single anorexic human
reported a “restricted” diversity of 10 fungal species
(Gouba et al. 2014a). However, neither of these num-
bers seem exceptional; other gut fungi studies report
0–24 fungal taxa in healthy individuals (Hallen-Adams
et al. 2015, Suhr 2015).
CROSS-KINGDOM INTERACTIONS
Interactions among microorganisms within the GI
tract have long been recognized as important determi-
nants of community function (Savage 1977). Inhabi-
tants are unlikely to act in isolation in the gut and
therefore live in complex associations with one
another. Residents of the gastrointestinal microbiota
are constantly interacting with one another, compet-
ing for nutrients and space and producing compounds
that directly inhibit growth or kill potential competi-
tors (Little et al. 2008). Microbes in the gut also may
form mutualistic and/or commensal interactions with
one another cooperating via syntrophy, using meta-
bolic waste products of another organism as nutrients,
and constructing interspecies antibiotic-resistant bio-
films (Rodríguez-Martínez and Pascual 2006, Woyke
et al. 2006). Hoffman et al. (2013) has best described
the correlations between fungi-bacteria and fungi-
archaea. Candida and Saccharomyces commonly co-
occur with bacterial taxa Faecalibacterium, Bacteroides,
Lachnospiraceae and Ruminococcaceae, and these
fungal genera are also positively associated with the
archaeon Methanobrevibacter and negatively associated
with the archaeon Nitrososphaera. Further analysis
showed that Candida was negatively associated with Bac-
teroides. Hallen-Adams and colleagues (2015) observed
a negative correlation between Escherichia/Shigella and
the fungiMalassezia and Trichosporon, and the presence
of Candida tropicalis was positively associated with Bac-
teroides and negatively associated with Eubacterium.
Bacteria and fungi indisputably interact physically
and chemically with one another within an ecosystem
(Peleg et al. 2010). These interactions influence over-
all survival, colonization and virulence. Perhaps the
most important bacterial-fungal interaction led to the
discovery of penicillin (Fleming 1929). Physical inter-
actions between fungi and bacteria include forming
mixed biofilms with one another and the ability of bac-
teria to attach to fungal hyphae, inhibiting filamenta-
tion and biofilm formation (Adam et al. 2002, Peleg
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et al. 2008). Bacteria also produce antifungal mole-
cules that affect morphology and virulence of Candida
(Hogan et al. 2004). Bacteria have the ability to modify
the environment by lowering the pH and preventing
hyphae formation by C. albicans (Buffo et al. 1984).
Bacteria and fungi are known to inhabit and interact
with one another at multiple human body sites. The
species composition of the two may become beneficial
or detrimental to the human host. Within the gastroin-
testinal microbiota, colonization resistance is a known
interaction that prevents overgrowth by endogenous
organisms. The bacterial microbiota reduces C. albi-
cans colonization by excluding and out-competing
Candida for adhesion sites and producing inhibitory
molecules (Kennedy and Volz 1985). Controlling fun-
gal colonization, especially by opportunists, with the
use of probiotic bacteria is appealing. One study
showed the probiotic bacteria Lactobacillus acidophilus
and Lactobacillus casei induce protection against sys-
temic candidiasis in mice (Wagner et al. 2000). Short-
chain fatty acids (butyric acid) produced by lactic
acid bacteria also inhibit filamentation and may pre-
vent C. albicans from causing disease in the gut (Noverr
and Huffnagle 2004a).
When broad-spectrum antibiotics are administered,
these have the potential to cause serious disruption
to the entire bacterial community in the GI tract, per-
turb the equilibrium and allow the host to become sus-
ceptible to infections by normally benign, commensal
fungi such as C. albicans (Samonis et al. 1993). Antibiot‐
ics are, therefore, a major risk factor for candidemia in
hospitalized patients (Wey et al. 1989, Nucci and
Colombo 2002, Zaoutis et al. 2010). Conversely post-
antibiotic recolonization of the bacterial gut micro-
biota is shaped and altered by the presence of Candida.
In the stomach of microbiome-disturbed mice C. albi-
cans prevents Lactobacillus regrowth after antibiotic
treatment and promotes colonization of Enterococcus
(Mason et al. 2012a). Presence of C. albicans in the
murine cecum after antibiotic treatment promotes
Bacteroidetes populations, Enterococcus faecalis persis-
tence, and inhibits Lactobacillus johnsonii (Mason et al.
2012b). Another recent study demonstrated that the
exogenous addition of C. albicans during treatment
with the cefoperazone in mice led to yeast overgrowth
and substantially altered reassembly of the bacte‐
rial community after treatment (Erb Downward
et al. 2013).
CONCLUSION AND FUTURE DIRECTIONS
Study of the gastrointestinal mycobiome is still in its
infancy. Given the few species consistently reported
in gut mycobiome studies (Candida spp. and other Sac-
charomycetalean yeasts, common environmental
molds such as Aspergillus, Cladosporium and Penicillium)
and the low abundance of fungi in the gut, it is unlikely
that fungi will be found to play as broad and diverse a
set of roles as gastrointestinal bacteria in host fitness
and well-being. The final word on gut fungal diversity
is yet to come; gut-fungal studies span nearly a century
(albeit with a .50 y gap, 1917–1969), yet species new
to the gut are reported in nearly every study. Some of
this diversity is illusory, and much represents environ-
mental and foodborne organisms that do not contrib‐
ute to gut ecology.
There remains much to learn and worth learning
about the mycobiota: the role of Candida species in a
healthy microbiome, for instance, the effect of diet
on mycobiota and the stability of the mycobiome over
time all require much larger and broader studies
than have been undertaken to satisfactorily address.
Well-designed studies, incorporating environmental
sampling and dietary data, are needed to determine
the role, if any, of environmental molds. A reliance
on BLAST-query results for identification may under-
represent as well as overrepresent diversity; in many
cases the closest BLAST hit does not allow species iden-
tification, and active members of the gut community
remain undescribed (e.g. Malassezia spp. and yeasts in
the Dipodascaceae; Hallen-Adams et al. 2015).
Metagenomic characterization of the gut myco-
biome is already possible in a targeted fashion for
organisms with sequenced genomes. Areas of interest
include many questions about Candida basic biology
(Is mating occurring? How do various conditions
[diet, microbial composition, host health and fitness]
influence the expression of virulence factors?) and
questions about nutrition—whether gut-adapted
Malassezia are accessing and using lipids from the
host’s diet (or directly from the host) and whether
any gut fungi are generating host-usable carbohydrates
from dietary fiber, as is well-documented in insects
(Nguyen et al. 2006) and herbivorous mammals
(Trinci et al. 1994).
The use of model systems, such as mice with limited,
defined microbiomes (gnotobiotic), remains underuti-
lized for fungi, although mouse models are a mainstay
for bacterial microbiome studies. Mice do not naturally
harbor Candida species and require some repression of
the natural microbiome to sustain Candida coloniza-
tion (Koh 2013), while the “natural” gut mycobiome
of laboratory mice is strongly influenced by the envi‐
ronment (food source, bedding etc.; Hallen-Adams
pers obs). Mouse studies to date deal primarily with
Candida and with disease (either candidiasis or the
role of Candida in other diseases such as colitis (e.g.
Jawhara and Poulain 2007, Szabo and MacCallum
2011), but the potential exists to gain a real under-
standing of fungal interactions, both with other
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microbes and with the host. As we forge ahead into this
exciting era it is hoped that mycologists will lead the
way to a better understanding of the role of fungi in
the human gut and throughout the body.
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